<?xml version='1.0' encoding='utf-8'?>
<document id="29966038"><sentence text="Evaluation of Food and Spherical Carbon Adsorbent Effects on the Pharmacokinetics of Roxadustat in Healthy Nonelderly Adult Male Japanese Subjects."><entity charOffset="33-39" id="DDI-PubMed.29966038.s1.e0" text="Carbon" /></sentence><sentence text="Roxadustat is a hypoxia-inducible factor prolyl hydroxylase inhibitor in late-stage clinical development for the treatment of anemia in chronic kidney disease" /><sentence text=" Spherical carbon adsorbent (SCA) is used in patients with chronic kidney disease and has been shown to impact absorption of certain concomitant drugs"><entity charOffset="11-17" id="DDI-PubMed.29966038.s3.e0" text="carbon" /></sentence><sentence text=" Two phase 1, open-label, randomized, crossover studies were conducted in healthy adult Japanese males to investigate the effect of food and SCA on the pharmacokinetics of a single oral dose of roxadustat"><entity charOffset="194-204" id="DDI-PubMed.29966038.s4.e0" text="roxadustat" /></sentence><sentence text=" Subjects in the food effect study received a single dose of 100-mg roxadustat under fed and fasted conditions" /><sentence text=" Subjects in the SCA/roxadustat drug-drug interaction study received a single dose of 100-mg roxadustat alone, concomitantly with SCA, and 1 and 2 hours before and after SCA to consider the real-world clinical situation and assess any potential impact of a lag time on the pharmacokinetics of roxadustat"><entity charOffset="293-303" id="DDI-PubMed.29966038.s6.e0" text="roxadustat" /></sentence><sentence text=" Primary outcomes for both studies were area under the concentration-time curve from the time of dosing extrapolated to infinity and maximum concentration of drug in blood plasma" /><sentence text=" In the food effect study (N = 16), the geometric mean ratio (fed/fasted) and 90% confidence interval for area under the concentration-time curve from the time of dosing extrapolated to infinity and maximum concentration of roxadustat were 94"><entity charOffset="224-234" id="DDI-PubMed.29966038.s8.e0" text="roxadustat" /></sentence><sentence text="44 (89" /><sentence text="93-99" /><sentence text="18) and 79" /><sentence text="88 (72" /><sentence text="09-88" /><sentence text="52), respectively" /><sentence text=" In the SCA/roxadustat drug-drug interaction study, all geometric mean ratios and 90% confidence intervals (roxadustat + SCA/roxadustat) were within the no-effect boundaries of 80% and 125%"><entity charOffset="125-135" id="DDI-PubMed.29966038.s15.e0" text="roxadustat" /></sentence><sentence text=" Roxadustat was generally well tolerated"><entity charOffset="1-11" id="DDI-PubMed.29966038.s16.e0" text="Roxadustat" /></sentence><sentence text=" The effect of food on the pharmacokinetics of roxadustat and the drug-drug interaction between roxadustat and SCA do not appear to be clinically relevant and support the safe use of roxadustat under these conditions"><entity charOffset="47-57" id="DDI-PubMed.29966038.s17.e0" text="roxadustat" /></sentence><sentence text="" /></document>